Interviews

When treatments get in the marketplace and are being recommended and used, there are actually still a lot of questions that can only be answered by researching real-world data, explained Joe V. Selby, MD, MPH, executive director of the Patient-Centered Outcomes Research Institute.

While it's exciting to see more and more physicians wanting to participate in clinical, they need a little background, support, and infrastructure to do so, said Robert Gabbay, MD, PhD, chief medical officer and senior vice president of Joslin Diabetes Center.

Sometimes patients are so concerned with being good patients that they simply agree to what the clinician has said without fully understanding, and it's important to ask questions and ensure their voices are heard, said Mary Lou Smith, MBA, co-founder of the Research Advocacy Network.

Only about one-fourth of all patients with behavioral health issues are diagnosed by a primary care provider and receive the appropriate treatment, said Paul Ciechanowski, MD, MPH.

Although hospital consolidation has not shown the benefits proponents had touted, it is inevitable that there will be consolidation in healthcare, because the environment is too challenging for smaller hospitals and many physician practices, explained Paul Ginsburg, PhD.

While the shift to cancer becoming more of a chronic disease does not have a huge change on the approach of the payer, there are some new challenges to address, said Jennifer Malin, MD, medical director for oncology at Anthem.

Patient engagement is in constant change and has evolved over the years into how care is delivered and how quality measures are developed, explained Marc Boutin, JD, chief executive officer

It's time for employers to consider more than just the medical benefits but the pharmacy benefits when it comes to specialty pharmaceuticals, said Cheryl Larson, BA, vice president of the Midwest Business Group on Health.

Restrictive prior authorization policies have made had a negative impact on schizophrenia patients, who tend to be an already-difficult population to treat, explained Dana Goldman, PhD.

While health information technology can be a solution for primary medication nonadherence, it can also be burdensome, according to Lauren Harner, JD, senior manager of policy at PhRMA.

Funding from the 21st Century Cures Act to the FDA will help expedite the drug approval process without sacrificing the accountability and effectiveness of the FDA's standards, said Congressman Frank Pallone, Jr (D-NJ).

Patients with diabetes whose traditions and culture includes celebrations with food should not take a negative approach to lifestyle management and dietary restrictions, according to Andrew Pumerantz, DO, FACP, of the Western Diabetes Institute.

Patients with diabetes are entering a new era in which they can take charge of their own health and medical needs and come ready with questions and ideas to manage their disease, said Kerri Sparling, writer/editor of patient diabetes blog Six Until Me.

With various healthcare stakeholders having different wants and needs from the healthcare system, meetings that bring all parties together in one room are important, according to Suzanne F. Delbanco, executive director of Catalyst for Payment Reform, and keynote speaker at the spring live meeting of the ACO and Emerging Healthcare Delivery Coalition.

There are many cost-related pieces in the grand picture of care that are devastating to families and patients, including copayments, hospital visit bills, transportation fees, and drug prices.

As the human genome becomes more of a part of standard care, both the physician's responsibilities to his or her patients and the way care is delivered changes, explained Mark Kris, MD, William and Joy Ruane chair in thoracic oncology at Memorial Sloan Kettering Cancer Center.

When patients overestimate the benefits of intervention and underestimate the harms of treatments, they may not be receiving the right forms of care that they should be, said Austin Frakt, PhD, health economist and researcher.

Taking on the patient mindset, truly getting to know the patient and then incorporating the patient's caregiver team are ways that will better engage patients in their care, said Joseph C. Kvedar, MD, vice president of Connected Health at Partners HealthCare.

The largest and perhaps most noticeable barrier standing between a successful collaboration of primary care physicians and specialists is the lack of communication, said Robert A. Gabbay, MD, PhD, chief medical officer and senior vice president of Joslin Diabetes Center.

Much of care coordination efforts for diabetes entail having the extra personnel to more closely manage patients and their behaviors, which in turn can improve medication adherence, said Paul Ciechanowski, MD, MPH, associate professor at the University of Washington.

The pay-for-performance model has come a long way in terms of how physicians are taking care of larger patients populations, according to Mitzi Wasik, PharmD, BCPS, director of Pharmacy Medicare Programs at Aetna, Inc.

The intersection of mental and physical health has been around now for quite some time, but the stigma attached to behavioral issues remains a barrier to patients getting the help they need, according to John Santopietro MD.

With various accountable care organization models that cover a wide range of health coverage plans, organizations with multiple models need to create a common framework for each market to follow in order to manage them.

Andrew Sussman, MD, president of MinuteClinic and senior vice president and associate chief medical officer of CVS Caremark, foresees a number of changes to come in terms of healthcare delivery in the US.

Although technology is becoming an increasingly important tool in healthcare, it should not be used with the intent to replace human care and relationships, explained Trishan Panch, MBBS, MP, chief medical officer of Wellframe.

Troy Trygstad, PharmD, MBA, PhD, vice president of pharmacy programs at Community Care of North Carolina, expressed the importance of a healthcare approach that concentrates on patient care and various delivery models that, in the end, promote long-term health and changes in health trajectory.

The introduction of biosimilars into the US market will not have a large impact on treatment costs until the volume of biosimiliars for different therapies increases, predicted Jennifer Malin, MD, medical director for oncology at Anthem.

Congressman Frank Pallone, Jr (D-NJ), explains the purpose of the National Institutes of Health Innovation Fund, which allows the organization to find cures for diseases that don't have 1 yet.